Short-term effects of prolactin on prostatic function in rats with lisuride-induced hypoprolactinaemia

H. Rui*, E. Haug†, B. Mevåg‡, Y. Thomassen§ and K. Purvis*

*Institute of Pathology, †Institute of Forensic Medicine, Rikshospitalet, and ‡Hormone Laboratory, Aker Hospital and §Institute of Occupational Health, Oslo, Norway

Summary. The effects of a single injection of ovine prolactin on prostatic function were monitored in intact, intact androgenized and castrated-androgenized rats rendered hypoprolactinaemic after 7 days of treatment with a potent dopamine agonist, lisuride. Hypoprolactinaemia was associated with reductions in ventral prostate weight, polyamine levels, lateral lobe zinc and the concentration of the ventral prostate protein prostatein, but an elevation in the level of cytosolic oestradiol binding. Whether these differences attained statistical significance depended on whether the animals were intact, intact-androgenized or castrated-androgenized. With the exception of ventral prostate weight and lateral lobe zinc concentrations, a single injection of prolactin restored or reversed these changes towards control levels within 12 h, which could not be explained by an indirect effect of the hormone on adrenal or testicular function. No effects of lisuride or prolactin were observed with regard to the content of fructose in the coagulating gland or in the degree of prolactin binding to prostatic membranes.

Introduction

There has accumulated convincing evidence that prolactin is necessary for the maintenance of accessory sex gland function. With regard to the rat prostate, prolactin has been reported to have positive effects on weight (Grayhack, 1963; Bartke & Lloyd, 1970; Negro-Vilar, Saad & McCann, 1977), nucleic acid levels (Thomas & Manandhar, 1975; Thomas, Manandhar, Keenan, Edwards & Klase, 1976; Prins & Lee, 1983), cell proliferation (Baker, Worgut, Santen, Jefferson & Bardin, 1977; McKeehan, Adams & Rosser, 1984), protein synthesis (Thomas & Manandhar, 1975), zinc uptake (Weinstein & Rosoff, 1972; Moger & Geschwind, 1972), citric acid concentration (Grayhack, 1963; Grayhack & Lebowitz, 1967; Walvoord, Resnick & Grayhack, 1976; Slaunwhite & Sharma, 1977) and the activity of acid phosphatase (Ghosh, Chatterjee & Ghosh, 1983). The above effects are in accordance with the presence of specific prolactin binding sites in the rat prostate (Aragona & Friesen, 1975; Hanlin & Yount, 1975; Thompson, Johnson & Brooks, 1982).

Work in this area has been facilitated by the use of dopamine agonists such as bromocriptine, which can specifically reduce circulating prolactin concentrations (Flückiger, 1976). The present work examined the short-term effects of prolactin withdrawal in the adult male rat, using another ergot derivative, lisuride, which is at least as potent as bromocriptine (Gräf, Neumann & Horowski, 1976), and water-soluble and therefore easier to administer. In addition to some of the conventional response indicators such as organ weight, zinc and fructose content, we also monitored oestrogen binding and prolactin binding, the levels of prostatein, a specific secretory protein from the ventral prostate (Lea, Petrusz & French, 1979), and the polyamines spermidine and spermine, and their diamine precursor putrescine.

Purvis, Clausen, Olsen, Haug & Hansson (1979) have indicated that a reduction in circulating prolactin has a negative effect on Leydig cell function in the rat, and inconsistent effects of prolactin suppression on circulating testosterone have been reported (Harper, Danutra, Chandler...
& Griffiths, 1976; Bartke, 1980). Experiments were therefore carried out using intact, intact androgenized and castrated-androgenized rats on three separate occasions. In addition to lisuride treatment, a subgroup of animals in each experiment also received a single dose of prolactin 12 h before being killed to examine whether any of the changes induced by prolactin withdrawal could be rapidly reversed.

Materials and Methods

Adult male Sprague–Dawley rats (150–180 days) were used in all experiments.

Effects of lisuride on circadian variations in hormone levels. This experiment was carried out to study the short-term effects of the dopamine agonist on circulating plasma hormones during the day to assess its efficacy in reducing plasma prolactin without disturbing other hormones. Fifty intact rats were randomly allocated to groups of 5. Half of the animals were treated with 25 µg lisuride (lisuride hydrogen maleate: Schering AG, Berlin, FRG) dissolved in 0.9% (w/v) NaCl (0.1 ml) twice a day (09:00 and 21:00 h), whereas controls received saline only. This dose of lisuride had been earlier judged to be the most effective concentration for inhibiting prolactin without causing undesirable behavioural effects (data not shown). On the 4th day of treatment rats were killed at 3, 6, 9 and 12 h after the morning injection. Rats killed at time zero did not receive this final injection. Trunk blood from these animals was collected and the plasma concentrations of prolactin, LH, testosterone and corticosterone were measured.

Effects of lisuride and prolactin on the prostate. Rats were allocated to 3 groups of 8 animals. Two of the groups were injected subcutaneously with 25 µg lisuride twice a day for 7 days, whereas the control group received saline. Towards the end of the study one of the lisuride-treated groups received 75 µg (2.3 i.u.) ovine prolactin (Sigma Chemical Co., St Louis, MO, U.S.A.) in 0.2 ml phosphate-buffered saline, pH 7.4, s.c.) concomitant with the last lisuride injection 12 h before autopsy. This experiment, which was initially carried out using intact rats, was repeated with intact animals in which circulating androgen was kept artificially at a constant level by daily injection of 100 µg testosterone propionate (in 0.1 ml peanut oil, i.m.) which was initiated concomitant with the first lisuride injection. A third study was also carried out with castrated rats that were given the same amount of androgen. The castration was performed via the scrotal route, and androgen replacement and lisuride treatment were initiated the following day. The animals were killed by decapitation, and trunk blood was collected in heparinized tubes. Plasma was obtained by centrifugation at 1500 g and 4°C for 10 min and stored at –70°C until used for assay of prolactin, LH and testosterone concentrations. Ventral lobes and coagulating glands were removed, and tissue from the lateral lobes was dissected out and frozen immediately in tubes in a solid CO₂-ethanol bath. Tissues were then transferred to –70°C until the day of assay. Oestradiol and prolactin binding were in all cases determined within 3 days. Seminal vesicles were ligated before removal, and the weight of the secretion was obtained as the difference between total organ weight and the weight after extrusion of the contents on absorbent paper.

Assay of plasma hormones. LH, prolactin and testosterone were determined using radio-immunoassay procedures described elsewhere (Purvis, Illius & Haynes, 1974; Haug & Gautvik, 1976; Purvis, Haug, Clausen, Naess & Hansson, 1977). The sensitivities and the within-assay coefficients of variation were 200 pg and < 7% for LH and prolactin, and 12.5 pg and < 6% for testosterone.

Corticosterone was measured by a competitive protein-binding assay also described earlier (Purvis, Calandra & Hansson, 1977). Assay sensitivity was 200 pg and the within-assay coefficient of variation was always < 10%.
Assay of prolactin binding. The details of the method have been published previously (Charreau et al., 1977); the method is based on the incubation of individual membrane preparations with iodinated human prolactin at room temperature for 16–18 h in the presence or absence of excess unlabelled hormone. In the experiment using intact androgenized rats, the binding was measured on pools of tissues. All determinations were carried out in triplicate, and the within-assay coefficient of variation was < 5%.

Assay of cytosolic oestrogen binding. Studies on the prostatic oestrogen receptor and validation of the receptor assays have been reported previously (Ginsburg, Jung-Testas & Baulieu, 1980; Jung-Testas et al., 1981; Purvis, Morkāš, Rui & Attaramadal, 1985). Tissue was homogenized in 5 volumes of Tris–HCl buffer (10 mm, pH 7.4) containing 1 mm-EDTA, 1 mm-2-mercaptoethanol and 250 mm-sucrose. The homogenate was centrifuged at 105 000 g for 1 h at 4°C and aliquants (200 µl) of the supernatant were incubated on ice for 16–18 h in the presence of a 40-fold excess of non-radioactive 5α-dihydrotestosterone. Parallel aliquants were incubated with a 100-fold excess of unlabelled oestradiol to evaluate the extent of non-specific binding. The total incubation volume was 300 µl. Unbound hormone was removed by incubation on ice for 10 min with dextran–charcoal followed by centrifugation. Scatchard analysis was carried out using the same procedure as above but after incubating with various amounts of [3H]oestradiol (0.2–3.0 nm). Non-specific binding was estimated at each point of the Scatchard plot and binding was expressed as fmol bound/mg protein. The within-assay coefficient of variation was < 3%.

Assay of prostatein. Ventral lobe prostatein content was determined by rocket electrophoresis as described by Lea et al. (1979). Aliquants (3–20 µl) of individual cytosols (105 000 g for 1 h, diluted 1:500) were run on polyacrylamide gels. In the experiment using intact androgenized rats, the assay was carried out on pooled cytosols. Duplicate or triplicate determinations were carried out, and results were expressed in arbitrary units in the form of cm rocket height. The within-assay coefficient of variation was < 8%.

Assay of zinc. Lateral lobe tissue was homogenized in 20 volumes of Tris–HCl buffer, and deproteinized in 1 volume of 10% trichloroacetic acid (TCA). A Perkin–Elmer model 5000 atomic absorption spectrophotometer equipped with a Zn-EDL lamp and the microcup flame atomization technique were used. Buffer–TCA blanks were assayed in parallel.

Assay of fructose. Coagulating gland cytosols (105 000 g supernatants) were deproteinized in 1 volume of 10% TCA, and fructose was determined according to the procedure of Ricterich (1969), which is based on the colorimetric determination of a yellow reaction product resulting from fructose and anthrone (Sigma Chemical Co.). The within-assay coefficient of variation was < 10%. Fructose measurement was not performed in the last experiment with castrated rats, because the previous experiments had failed to reveal any effect of prolactin on this measure.

Assay of polyamines. The polyamines spermidine and spermine and their diamine precursor, putrescine, were determined by a high-pressure liquid chromatography technique (Laboratory Data Control, Milton Roy Co., Riviera Branch, FL, U.S.A.), using a procedure which was a slight modification of that of Seiler & Knödgen (1978). Briefly, 100 µl samples of cytosols (20 000 g for 30 min) from ventral lobe tissue were mixed with 300 µl of internal standard solution (1,6-diaminohexane, 25 nmol in water) and deproteinized with 400 µl 0·4 M-perchloric acid (PCA) on ice for 20 min, followed by centrifugation at 2000 g for 30 min. A sample (100 µl) of the supernatant was diluted with 100 µl water and mixed with 100 mg NaHCO3 and 400 µl dansyl chloride (Sigma Chemical Co.; 0.11 µ in acetone). The reaction mixture was allowed to stand overnight in the dark at room temperature. Excess dansyl chloride was removed by addition of 100 µl L-proline (1·3 µ in water) followed by a further 30 min of incubation in the dark. The contents of the tubes were then dried at 65°C under a stream of air, dissolved in 100 µl water, and extracted with 500 µl toluene. An aliquant (300 µl) of the toluene phase was evaporated to dryness and dissolved in a final volume of
600 µl methanol. A 20-µl sample was applied to the column (250 × 4.6 mm i.d., Supelcosil LC-18, particle size 5 µm, Supelco Inc., Pasadena, CA, U.S.A.) by an autosampler, and separation of the dansyl derivatives was obtained using a linear methanol/water gradient changing from 65 to 100% methanol (Ratburn Chemicals Ltd, Walkerburn, U.K.; HPLC grade) in 23 min at a flow rate of 1 ml/min. Elution times for the dansyl derivatives of putrescine, spermidine and spermine were about 13.4, 18.9 and 22.5 min, respectively, whereas the internal standard eluted at 15.1 min. External standards were run after every 7th sample, and contained 93.75, 125, 375 and 125 pmol putrescine, internal standard, spermidine and spermine, respectively. The assay sensitivity was about 10 pmol for the various polyamines, and the within-assay coefficient of variation was < 4%. The fluorescence detector used was equipped with an excitation filter of 340 nm and an emission filter of 460 nm.

Statistics. Results were analysed by one-way analysis of variance after logarithmic transformation of the data.

Results

Effects of lisuride on circadian variations in hormone concentrations

As can be seen from Text-fig. 1, prolactin concentrations remained low during the whole observation period in lisuride-treated animals. Prolactin concentrations in the control animals were variable and by 12 h the values were not significantly different from those of lisuride-treated rats.

Text-fig. 1. Plasma concentrations of hormones in control and lisuride-treated intact male rats killed every 3 h during a 12-h period after the last injection. Before the day of autopsy the animals had been injected s.c. twice daily with 25 µg lisuride (●——●) or saline (○——○) for 3 days. Rats killed at time zero did not receive the final injection. Vertical bars represent geometric means ± s.e. for 5 rats/group.
Plasma concentrations of prolactin, testosterone and LH after 7 days of lisuride treatment (25 µg s.c. twice daily) of intact, intact-androgenized (100 µg testosterone propionate daily) and castrated-androgenized rats. The results are obtained from three separate studies. Rats in one of the lisuride-treated groups (L/P) received a single s.c. injection of ovine prolactin (75 µg) concomitant with the last lisuride injection 12 h before autopsy. Control animals (C) received saline. Vertical bars represent 95% confidence limits of geometric means (N = 8).

***Values significantly different from those of control rats, \( P < 0.001 \).

LH and corticosterone concentrations were not affected by lisuride treatment. Testosterone values exhibited an apparent bimodal response to the drug, showing an initial reduction (to 28% of control value, \( P < 0.02 \)) 3 h after injection and an elevation (to 169% of control value, \( P < 0.05 \)) after a further 3 h, followed by a gradual normalization to control levels over the next 6 h.

**Effects of lisuride and prolactin on the prostate**

Plasma prolactin concentration was markedly reduced in lisuride-treated rats, an effect also observed in animals that had received a single prolactin injection 12 h before autopsy in addition to lisuride treatment (Text-fig. 2), which partly reflects the specificity of the rat prolactin assay and partly the rapid clearance of this hormone from the circulation. No significant deviation from control levels was observed with regard to plasma testosterone or LH, although there was a tendency in intact rats for testosterone to be elevated 12 h after the prolactin injection. In the intact animals, testicular weight was significantly reduced by lisuride treatment (\( P < 0.01 \)), an effect which was not
Table 1. Testicular weight, lateral lobe zinc and coagulating gland fructose concentrations in control (C), lisuride-treated (L) and lisuride-treated rats exposed to a single dose of prolactin 12 h before autopsy (L/P)

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Intact rats</th>
<th>Intact-androgenized rats†</th>
<th>Castrated-androgenized rats†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testicular weight (g)</td>
<td>C</td>
<td>4.1 (4.0-4.3)</td>
<td>4.0 (3.6-4.4)</td>
</tr>
<tr>
<td></td>
<td>L</td>
<td>3.7 (3.6-3.9)***</td>
<td>4.0 (3.9-4.1)</td>
</tr>
<tr>
<td></td>
<td>L/P</td>
<td>3.8 (3.7-4.0)***</td>
<td>4.0 (3.8-4.3)</td>
</tr>
<tr>
<td>Lateral lobe zinc (pg/g wet wt)</td>
<td>C</td>
<td>185 (164-210)</td>
<td>163 (109-244)</td>
</tr>
<tr>
<td></td>
<td>L</td>
<td>146 (117-183)*</td>
<td>96 (58-142)**</td>
</tr>
<tr>
<td></td>
<td>L/P</td>
<td>122 (77-191)</td>
<td>114 (83-157)***</td>
</tr>
<tr>
<td>Coagulating gland fructose (pg/mg protein)</td>
<td>C</td>
<td>34.7 (33-36)</td>
<td>43.6 (39-49)</td>
</tr>
<tr>
<td></td>
<td>L</td>
<td>34.9 (30-41)</td>
<td>41.2 (34-50)</td>
</tr>
<tr>
<td></td>
<td>L/P</td>
<td>34.0 (29-40)</td>
<td>41.8 (35-51)</td>
</tr>
</tbody>
</table>

Values are geometric means (with 95% confidence limits) for 8 rats/group.
*P < 0.05; **P < 0.02; ***P < 0.01 for differences from control levels.
†100 µg testosterone propionate i.m. daily during the treatment period.

Text-fig. 3. Ventral lobe prostate weight, ventral lobe prostaticin concentration and seminal vesicle secretion in control (C), lisuride-treated (L) and lisuride-treated rats exposed to a single dose of ovine prolactin (L/P). Prostaticin determinations in intact-androgenized rats were carried out on pools of tissue (s.d. of triplicate measurements are indicated). Vertical bars represent 95% confidence limits of geometric means (N = 8). Values significantly different from control levels; *P < 0.05; **P < 0.01; ***P < 0.001.
Text-fig. 4. Binding of oestradiol and prolactin in the cytosols and membranes, respectively, in control (C), lisuride-treated (L) and lisuride-treated rats exposed to a single dose of ovine prolactin (L/P). Data on oestradiol binding in androgenized-castrated rats is derived from Scatchard analysis on pooled tissue; the shaded area of these columns represents the lower affinity component (see Text-fig. 5). Measurement of prolactin binding in intact-androgenized rats was also carried out on pooled membranes (s.d. of triplicate determinations are indicated). Vertical bars represent 95% confidence limits of geometric means (N = 8). *P < 0.05 compared with control level.

reversed within 12 h of a single prolactin injection (P < 0.01; Table 1). No effect on testicular weight was observed in intact androgenized rats. Table 1 also shows the concentration of zinc in the lateral lobes and fructose in the coagulating glands of these animals. The zinc concentration was reduced by lisuride treatment, but showed no indication of reversal towards control levels within 12 h of exposure to prolactin. Coagulating gland fructose was not altered by lisuride or prolactin.

The effects of 7 days of lisuride treatment and lisuride combined with a single injection of prolactin on ventral prostate weight, ventral prostate content of prostatin and seminal vesicle secretion are shown in Text-fig. 3. Lisuride significantly reduced prostate weight in intact-androgenized (P < 0.001) and castrated-androgenized (P < 0.05) rats. A single dose of prolactin at the end of the treatment period did not reverse these weights to normal, at least within 12 h. The greatest

Text-fig. 5. Scatchard plots of specific oestradiol binding to pooled cytosols from control (C), lisuride-treated (L) and lisuride-treated rats exposed to a single dose of prolactin (L/P).
inhibitory effect of the drug was seen in intact-androgenized rats, in which the mean weight of the prostate in lisuride-treated animals was reduced to 64% of values in controls.

Prostatein was also affected to some degree by prolactin withdrawal, being reduced to 65, 68 and 93% after lisuride treatment in intact, intact-androgenized and castrated-androgenized animals, respectively. In intact animals, prolactin increased the concentration of this protein to a level which was not significantly different from control (Text-fig. 3).

The amount of secretion in the seminal vesicles in lisuride-treated rats was reduced to 80% ($P < 0.01$) in intact, 63% (not significant) in intact-androgenized and 81% ($P < 0.05$) in castrated-androgenized animals as compared to their respective control groups (Text-fig. 3). In all three experiments prolactin reversed this change when administered 12 h before autopsy.

The binding of oestradiol in ventral prostate cytosol was elevated significantly by lisuride treatment ($P < 0.05$) only in intact-androgenized rats (Text-fig. 4). In the experiment with castrated-androgenized rats, Scatchard analysis of the binding was performed, which indicated that the effect

![Graph](image-url)

**Text-fig. 6.** Ventral prostate spermine, spermidine and putrescine concentrations in control (C), lisuride-treated (L) and lisuride-treated rats exposed to a single dose of ovine prolactin (L/P). Data are obtained from two separate experiments using intact-androgenized (100 μg testosterone propionate, i.m. daily) or castrated-androgenized animals. Vertical bars represent 95% confidence limits of geometric means ($N = 8$). *$P < 0.05$; **$P < 0.001$ compared with control levels.
involved two relatively high-affinity components, with apparent $K_d$ values of $5 \times 10^{-10}$ M and $3.4 \times 10^{-9}$ M, respectively (Text-fig. 5). Prolactin administration reduced oestrogen binding ($P < 0.05$) in intact-androgenized animals.

The binding of prolactin to ventral prostate membranes did not exhibit a consistent response to lisuride or prolactin (Text-fig. 4).

Cytosolic putrescine concentration was unaffected by treatment with lisuride or prolactin, but spermine was reduced to 47% ($P < 0.001$) and 74% ($P < 0.02$) of the values in intact-androgenized and castrated-androgenized rats, respectively (Text-fig. 6). Corresponding values for spermidine were 67% ($P < 0.05$) and 81% ($P < 0.05$). By 12 h after a single prolactin injection, spermidine levels were restored or almost restored to control values, while those of spermine responded to a lesser degree.

## Discussion

In agreement with numerous reports the present study provides clear evidence that prolactin is necessary to maintain the integrity of at least some aspects of accessory sex gland function in the male rat. The degree to which prolactin withdrawal and addition influenced certain of the prostatic characteristics differed between the different experiments and may be related to differences in the concentrations of circulating androgen. The major stimulus to prostatic growth and function is testosterone, and the extent to which the prostatic cells are primed by this steroid may determine the degree of response to prolactin deficiency or excess. This interaction between androgen and prolactin may be one of the reasons why differences attained statistical significance in some experiments and not in others. However, it should be emphasized that the directions of these changes were the same in all three studies and therefore further evidence of a treatment effect.

Ventral prostate weights of control animals differed between the three studies, indicating that the degree of androgenization of the animals may have differed in the three experiments, despite the fact that this was not evident from the circulating testosterone concentrations. Indeed, the effects of prolactin were less obvious in the third study in which the lowest control prostate weights were recorded, suggesting that a particular threshold of androgenization may be necessary before the effects of prolactin withdrawal and addition are clearly manifested.

Another consideration in the interpretation of these studies is the efficacy with which lisuride removes prolactin from the peripheral circulation. All 4 studies indicated that the dose of lisuride used could not completely remove prolactin from the circulation. However, it is impossible to gauge how effective this basal level of prolactin secretion is in maintaining prostatic function, thereby reducing the difference from control levels.

Prolactin exerted relatively rapid effects on certain aspects of prostatic and vesicular function in prolactin-deficient rats, whereas other values appeared to require longer periods of exposure before returning to control levels. The reductions in the volume of vesicular secretion and the ventral prostate concentrations of prostatein and spermidine after lisuride treatment were all reversed towards control levels 12 h after a single prolactin injection. Several aspects of prostatic and seminal vesicle function were influenced by this hormone, whereas others (ventral lobe prolactin binding and coagulating gland fructose) were unaffected. Most of the characteristics examined were stimulated by prolactin but at least one, cytosolic oestrogen binding, appeared to be inversely related to circulating prolactin concentrations. Since lisuride administration was continued in the rats receiving prolactin, these rapid effects can be attributed to alterations in circulating prolactin and not to direct effects of the drug on the glands.

One of the potential complications in studies on prolactin withdrawal on androgen target organs is that some of the effects that are observed may be a result of the effect of prolactin on Leydig cell function. Several authors have shown that prolactin withdrawal has marked effects on the steroidogenic response of rat Leydig cells to LH (Bex & Bartke, 1977; Purvis et al., 1979).
Indeed, in intact rats there was a tendency for blood testosterone to be reduced in lisuride-treated animals and stimulated 12 h after prolactin injection. Testicular weights in this first study were also reduced in prolactin-deficient animals to a small but significant degree, indicating possible direct effects at the Leydig cell level.

The separate study on the effects of lisuride on various circulating hormones in intact rats indicated that the androgen concentrations observed in the treated animals at the time of autopsy altered markedly in relation to the time of the last injection. Such findings suggest that caution should be exercised in interpreting drug effects on the pituitary-testicular axis when they are based on single hormone determinations at a particular time after drug administration. Indeed, in the intact rats of this study, lisuride exerted both stimulatory and inhibitory effects on androgen values depending on the time of autopsy. For this reason in two of the subsequent studies plasma testosterone was kept artificially stable by exogenous administration to rule out hidden effects of prolactin withdrawal on the testis which could confound interpretation of the prostatic effects.

The fact that the majority of effects observed in intact rats were confirmed in these androgen-substituted animals indicated that an androgen deficiency could not explain the drug’s influence on the prostate. Moreover, there was no indication that adrenal function was disturbed by lisuride, as judged by the levels of circulating corticosterone in the treated animals, reducing the possibility that these prostatic effects could be explained by androgens from an adrenal source.

The fact that spermidine and spermine and not their diamine precursor putrescine were lowered by lisuride treatment of androgen-treated rats indicated a relatively greater effect on the enzyme S-adenosyl-l-methionine-decarboxylase than on ornithine decarboxylase. These enzymes are recognized as rate-limiting in the polyamine biosynthetic pathway (Pegg, Lockwood & Williams-Ashman, 1970). Prolactin has been reported to influence the polyamine values in a variety of tissues (Richards, 1975), and these amines are involved in the regulation of growth and protein synthesis in several organs including the prostate (Heston, Kadmon, Lazan & Fair, 1982; Herr & Kleinert, 1984), where they also represent major secretory components (Mann & Lutwak-Mann, 1981).

An observation which is more difficult to explain is the apparent interaction between prolactin and the binding of oestradiol to components in the prostatic cytosol. Scatchard analysis revealed that the hormone appeared to exert effects on one of the two binding components which can be demonstrated in the cytosol, the relatively lower-affinity high-capacity component which appears to be distinct from the classical oestrogen receptor (Peruzzi et al., 1985). Because the analysis was carried out on pools of tissue it was not possible in this study to obtain statistical proof for the apparent effect on the low affinity component. The mechanism of this interaction is, however, currently being investigated. The apparent lack of effects of prolactin withdrawal and addition on the levels of its own membrane receptor supports previous observations indicating that this receptor is relatively resistant to up or down regulation by prolactin in this gland (Kledzik, Marshall, Campbell, Gelato & Meites, 1976; Barrey, Shani & Barzilai, 1979).

Numerous reports have indicated that the lateral lobes of the rat are particularly sensitive to prolactin (Grayhack & Lebowitz, 1967; Moger & Geschwind, 1972; Prins & Lee, 1982). In the present report the zinc content of the lateral lobe was used as a functional indicator for this tissue and, in apparent confirmation of these earlier findings, prolactin withdrawal was associated with a decrease in the tissue concentration of the metal. However, no evidence was obtained indicating that prolactin treatment could reverse these changes, at least within 12 h of injection. Such results may indicate that the biochemical mechanisms underlying zinc uptake may be only slowly induced or that the rate of uptake of this metal ion when returned to normal is of such a low order that it takes time for differences to be manifest.

The present study confirms a role for prolactin in prostatic function in the rat, but also extends previous observations by demonstrating a complex interaction of the hormone with several aspects of prostatic biochemistry, including the levels of polyamines, prostatein and oestrogen binding. Rui, Gordeladze, Gautvik & Purvis (1984) have presented indirect evidence that prolactin may modify the local levels of prostaglandin E-1 in prostatic tissue, and current views support the
idea that this may mediate at least some of the effects of prolactin on target organs such as the mammary gland (Horrobin, 1979).

We thank D. O. Lea, Haukeland Hospital, Bergen, for the gift of prostatein antiserum, Dr K. Eliassen and Dineke Grønnseth at the Veterinary College, University of Oslo, for help and guidance in the establishment of the polyamine assay; and Inger Brekke and Lise Mørkás for skillful technical help. The study was supported by Norsk Forening til Kreftens Bekjempelse and Landsforeningen mot Kreft. H.R. is in receipt of a NAVF scholarship.

References


Received 28 December 1984